Infectious Diseases Service, University Hospital and University of Lausanne, Lausanne, Switzerland.
Department of Radiology, University Hospital and University of Lausanne, Lausanne, Switzerland.
Clin Infect Dis. 2021 Dec 6;73(11):e4189-e4196. doi: 10.1093/cid/ciaa1408.
Lung ultrasonography (LUS) is a promising pragmatic risk-stratification tool in coronavirus disease 2019 (COVID-19). This study describes and compares LUS characteristics between patients with different clinical outcomes.
Prospective observational study of polymerase chain reaction-confirmed adults with COVID-19 with symptoms of lower respiratory tract infection in the emergency department (ED) of Lausanne University Hospital. A trained physician recorded LUS images using a standardized protocol. Two experts reviewed images blinded to patient outcome. We describe and compare early LUS findings (≤24 hours of ED presentation) between patient groups based on their 7-day outcome (1) outpatients, (2) hospitalized, and (3) intubated/dead. Normalized LUS score was used to discriminate between groups.
Between 6 March and 3 April 2020, we included 80 patients (17 outpatients, 42 hospitalized, and 21 intubated/dead). Seventy-three patients (91%) had abnormal LUS (70% outpatients, 95% hospitalized, and 100% intubated/dead; P = .003). The proportion of involved zones was lower in outpatients compared with other groups (median [IQR], 30% [0-40%], 44% [31-70%], 70% [50-88%]; P < .001). Predominant abnormal patterns were bilateral and there was multifocal spread thickening of the pleura with pleural line irregularities (70%), confluent B lines (60%), and pathologic B lines (50%). Posterior inferior zones were more often affected. Median normalized LUS score had a good level of discrimination between outpatients and others with area under the ROC of .80 (95% CI, .68-.92).
Systematic LUS has potential as a reliable, cheap, and easy-to-use triage tool for the early risk stratification in patients with COVID-19 presenting to EDs.
肺部超声(LUS)是一种很有前途的 2019 冠状病毒病(COVID-19)实用风险分层工具。本研究描述并比较了不同临床结局患者的 LUS 特征。
前瞻性观察性研究,纳入洛桑大学医院急诊科(ED)因下呼吸道感染症状且经聚合酶链反应(PCR)确诊的成年 COVID-19 患者。一名经过培训的医生使用标准化方案记录 LUS 图像。两名专家在不了解患者结局的情况下对图像进行盲法评估。我们根据患者 7 天结局(1)门诊、(2)住院和(3)插管/死亡,描述并比较了早期 LUS 表现(ED 就诊后≤24 小时)。使用归一化 LUS 评分来区分各组。
在 2020 年 3 月 6 日至 4 月 3 日期间,共纳入 80 例患者(门诊患者 17 例,住院患者 42 例,插管/死亡患者 21 例)。73 例(91%)患者的 LUS 异常(门诊患者 70%,住院患者 95%,插管/死亡患者 100%;P=0.003)。与其他组相比,门诊患者受累区域的比例较低(中位数[四分位间距],30%[0-40%],44%[31-70%],70%[50-88%];P<0.001)。主要异常模式为双侧,胸膜不规则增厚伴多发胸膜线增厚(70%)、融合 B 线(60%)和病理性 B 线(50%)。后下区更常受累。归一化 LUS 评分中位数在区分门诊患者和其他患者方面具有良好的区分度,ROC 曲线下面积为 0.80(95%CI,0.68-0.92)。
系统 LUS 具有成为一种可靠、廉价且易于使用的分诊工具的潜力,可用于对急诊科就诊的 COVID-19 患者进行早期风险分层。